Carmichael Hill & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-696
| Closed | -$7.78K | – | 693 |
|
|
2023
Q3 | $7.78K | Hold |
696
| – | – | ﹤0.01% | 493 |
|
|
2023
Q2 | $14.9K | Hold |
696
| – | – | 0.01% | 423 |
|
|
2023
Q1 | $28.1K | Hold |
696
| – | – | 0.01% | 348 |
|
|
2022
Q4 | $32.4K | Hold |
696
| – | – | 0.02% | 328 |
|
|
2022
Q3 | $36K | Hold |
696
| – | – | 0.02% | 317 |
|
|
2022
Q2 | $33K | Hold |
696
| – | – | 0.02% | 322 |
|
|
2022
Q1 | $50K | Hold |
696
| – | – | 0.02% | 290 |
|
|
2021
Q4 | $52K | Hold |
696
| – | – | 0.02% | 279 |
|
|
2021
Q3 | $40K | Hold |
696
| – | – | 0.02% | 313 |
|
|
2021
Q2 | $31K | Hold |
696
| – | – | 0.02% | 355 |
|
|
2021
Q1 | $34K | Hold |
696
| – | – | 0.02% | 327 |
|
|
2020
Q4 | $29K | Hold |
696
| – | – | 0.02% | 337 |
|
|
2020
Q3 | $32K | Hold |
696
| – | – | 0.02% | 297 |
|
|
2020
Q2 | $35K | Hold |
696
| – | – | 0.03% | 276 |
|
|
2020
Q1 | $36K | Hold |
696
| – | – | 0.03% | 256 |
|
|
2019
Q4 | $43K | Buy |
+696
| New | +$43K | 0.03% | 261 |
|